Expand ICCM Menu
ICCM MENU

ICCM Latest Press Releases

-- January 28, 2026 --

IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer PRNewswire 8:30 AM

-- January 12, 2026 --

IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense Sales PRNewswire 8:30 AM

-- December 17, 2025 --

IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense Cryoablation for Low-Risk Breast Cancer PRNewswire 8:30 AM

-- December 10, 2025 --

IceCure's ProSense Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting PRNewswire 8:30 AM

-- December 5, 2025 --

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes PRNewswire 8:30 AM

-- November 19, 2025 --

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 PRNewswire 8:54 AM

-- November 18, 2025 --

IceCure's ProSense Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer PRNewswire 8:30 AM

-- November 14, 2025 --

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification PRNewswire 4:30 PM

-- November 12, 2025 --

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025 PRNewswire 8:30 AM

-- November 10, 2025 --

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction PRNewswire 8:30 AM

-- November 3, 2025 --

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival PRNewswire 8:30 AM

-- October 13, 2025 --

IceCure's ProSense Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances PRNewswire 8:31 AM

-- October 9, 2025 --

IceCure Medical to Attend the 2025 Maxim Growth Summit PRNewswire 8:39 AM

-- October 3, 2025 --

IceCure Medical's ProSense Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care PRNewswire 12:28 PM
IceCure Receives FDA Marketing Authorization for ProSense Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above PRNewswire 12:19 PM

-- September 30, 2025 --

IceCure's ProSense at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented PRNewswire 8:31 AM

-- September 22, 2025 --

IceCure's ProSense Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented PRNewswire 8:30 AM

-- September 18, 2025 --

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense Cryoprobes PRNewswire 8:30 AM

-- September 15, 2025 --

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense Cryoablation System for Breast Cancer and Other Indications PRNewswire 8:30 AM

-- September 8, 2025 --

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense Cryoablation Achieves Highest Complete Ablation Rate PRNewswire 8:30 AM
Market Data Delayed 15 Minutes